CEL

Celadon Pharmaceuticals AIM:CEL Stock Report

Last Price

UK£0.54

Market Cap

UK£33.0m

7D

1.9%

1Y

n/a

Updated

30 Nov, 2022

Data

Company Financials
CEL fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

CEL Stock Overview

Celadon Pharmaceuticals Plc, a pharmaceutical company, engages in the research, manufacture, and supply of cannabinoids for use in approved medicines.

Celadon Pharmaceuticals Plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Celadon Pharmaceuticals
Historical stock prices
Current Share PriceUK£0.54
52 Week HighUK£1.50
52 Week LowUK£0.49
Beta0
1 Month Change-24.11%
3 Month Change-33.13%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-63.10%

Recent News & Updates

Recent updates

Shareholder Returns

CELGB PharmaceuticalsGB Market
7D1.9%1.7%0.9%
1Yn/a7.0%-6.7%

Return vs Industry: Insufficient data to determine how CEL performed against the UK Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how CEL performed against the UK Market.

Price Volatility

Is CEL's price volatile compared to industry and market?
CEL volatility
CEL Average Weekly Movement4.9%
Pharmaceuticals Industry Average Movement5.7%
Market Average Movement5.9%
10% most volatile stocks in GB Market11.0%
10% least volatile stocks in GB Market2.9%

Stable Share Price: CEL is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: CEL's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20184Jim Shorthttps://www.celadonpharma.co.uk

Celadon Pharmaceuticals Plc, a pharmaceutical company, engages in the research, manufacture, and supply of cannabinoids for use in approved medicines. The company focuses on growing indoor hydroponic THC cannabis for use in medicinal products used to treat chronic pain. It also intends to conduct research into cannabinoids for use in chronic pain, as well as other conditions, such as autism and multiple sclerosis.

Celadon Pharmaceuticals Plc Fundamentals Summary

How do Celadon Pharmaceuticals's earnings and revenue compare to its market cap?
CEL fundamental statistics
Market CapUK£32.99m
Earnings (TTM)-UK£11.52m
Revenue (TTM)UK£11.26k

2,972x

P/S Ratio

-2.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CEL income statement (TTM)
RevenueUK£11.26k
Cost of RevenueUK£23.67k
Gross Profit-UK£12.41k
Other ExpensesUK£11.50m
Earnings-UK£11.52m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.19
Gross Margin-110.22%
Net Profit Margin-102,299.72%
Debt/Equity Ratio0.4%

How did CEL perform over the long term?

See historical performance and comparison